Saturday 17 October 2026
Export NKGN’s income statement to Excel — free account
NKGen Biotech, Inc.
NKGN Healthcare Biotechnology
NKGen Biotech, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $77,000.00. In the quarter to March 2025, EPS grew 232.0% and free cash flow grew 28.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.01
0.00
0.00%
Follow NKGN
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Trend | 2025e | 2026e | 2027e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 9.63 | 9.63 | 2.71 | 0.20 |
Analyst estimates 2025–2027 Powerpack |
|||
| High | — | — | — | — | — | — | 10.00 | 10.01 | 12.88 | 4.06 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 6 | 4 | 63 | 26 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.02 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 0 | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | 76.62 | — | — | |||||
| EBT | — | — | — | — | — | — | (1) | (27) | (83) | (44) | |||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | (34,736.36) | 0.00 | 0.00 | |||||
| Net income | — | — | 0 | — | — | — | (1) | (27) | (83) | (44) | |||||
| Depreciation | — | — | — | — | — | — | — | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.01 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | (0.06) | (4.21) | (5.38) | (1.54) | |||||
| Cash flow | — | — | — | — | — | — | (0.10) | (3.55) | (1.42) | (0.72) | |||||
| Capex | — | — | — | — | — | — | 0.00 | (0.03) | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | — | (0.10) | (3.57) | (1.43) | (0.72) | |||||
| Book value | — | — | — | — | — | — | (0.72) | 0.25 | (3.80) | (2.42) | |||||
| Shares, m | — | — | — | — | — | — | 15 | 6 | 15 | 29 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | — | — | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | — | — | |||||
| P/B | — | — | — | — | — | — | — | 40.46 | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | (3.32) | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (2) | (23) | (22) | (21) | ||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | — | — | — | (2) | (23) | (22) | (21) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 1 | (14) | (38) | (56) | ||||
| Total debt | — | — | — | — | — | — | — | 12 | 10 | 43 | |||||
| Net debt | — | — | — | — | — | — | (2) | 12 | 10 | 43 | |||||
| Shareholders’ equity | — | — | — | — | — | — | (11) | 2 | (59) | (70) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | (1.14) | (28.09) | (505.65) | (270.76) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | (116.15) | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | — | 0.00 | 573.40 | 290.40 | 68.87 | |||||
Negative figures in brackets.
Fiscal years to Dec 2022 · latest quarter Dec 2022
Charts ten years each
NKGen Biotech, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics Ltd. Sponsored ADR | $9.4M | — (loss-making) | — | — | n/m | +47.89% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MTVA MetaVia Inc. | $9.0M | — (loss-making) | — | — | n/m | −22.42% (below 0%: shrinking) | — | 0.00% | Compare |
| JAGX Jaguar Animal Health, Inc. | $8.9M | 0.0× | — (loss-making) | −58.88% (below 0%: shrinking) | n/m | +13.83% (above 0%: growing) | 15.84% | (620.16%) | Compare |
| NKGN NKGen Biotech, Inc. | $8.8M | — (loss-making) | — | — | n/m | +28.68% (above 0%: growing) | 100.00% | 0.00% | |
| CSCIF COSCIENS Biopharma Inc. | $8.6M | 1.0× | — | +30.04% (above 0%: growing) | n/m | +113.30% (above 0%: growing) | 55.27% | 13.43% | Compare |
| IMRN IMMURON | $8.3M | — (loss-making) | — | +757.00% (above 0%: growing) | +12.00% (above 0%: growing) | +42.55% (above 0%: growing) | 72.16% | 0.00% | Compare |
| ADIL Adial Pharmaceuticals, Inc. | $8.3M | — (loss-making) | — | — | n/m | −263.66% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BOLT Bolt Biotherapeutics, Inc. | $8.2M | — (loss-making) | — (loss-making) | −99.72% (below 0%: shrinking) | n/m | +38.87% (above 0%: growing) | 100.00% | (167,480.00%) | Compare |
| SNTI Senti Biosciences, Inc. | $8.1M | — (loss-making) | — (loss-making) | −98.68% (below 0%: shrinking) | n/m | −7.48% (below 0%: shrinking) | 100.00% | (85,229.41%) | Compare |
| Median of peers | $8.4M | — | — | −58.88% | — | +26.35% | 55.27% | 0.00% |
NKGen Biotech, Inc. (NKGN) key facts
- NKGen Biotech, Inc. (NKGN) is a Biotechnology company in the Healthcare sector.
- NKGen Biotech, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $77,000.00.
- As of October 15, 2026, NKGN traded at $0.01, a market capitalization of $8.8 million.
- Return on equity was 68.9% and debt-to-equity -0.59.
- Its Altman Z-score is −10.19 (distress zone) for fiscal 2022.